Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290
This study is recruiting at 17 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Squamous Lung Cancer
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- NSCLC
- Advanced Lung Carcinoma
- Epidermal Growth Factor Receptor C797S
- Epidermal Growth Factor Receptor G719X
- EGF-R Positive Non-Small Cell Lung Cancer
- EGFR-TKI Resistant Mutation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Black Diamond Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- November 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama · Birmingham, AL
Arizona · 1
- Banner MD Anderson Cancer Center · Gilbert, AZ
California · 2
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, CA
- Cedars Sinai Medical Center · Los Angeles, CA
District of Columbia · 1
- Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., DC
Florida · 2
- Mayo Clinic- Jacksonville · Jacksonville, FL
- Miami Cancer Institute - Baptist Health South Florida · Miami, FL
Hawaii · 1
- UHP- University of Hawaii Cancer Center · Honolulu, HI
Illinois · 1
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, IL
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Minnesota · 1
- Mayo Clinic- Rochester · Rochester, MN
New York · 1
- Montefiore Medical Center · The Bronx, NY
Pennsylvania · 1
- University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, PA
Tennessee · 1
- Tennessee Oncology · Nashville, TN
Virginia · 2
- Inova Schar Cancer Institute · Fairfax, VA
- Next Oncology · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Center/University of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.